| Notes
|
A potential mechanism involved in hemangioma formation is the alteration of the FLT1 receptor signaling pathway in endothelial and/or pericytic cells. A potential mechanism involved in hemangioma formation is the alteration of the FLT1 receptor signaling pathway in endothelial and/or pericytic cells. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene is associated with prostate cancer. Blocking VEGF and PDGF receptor signaling in cardiac allografts has distinctive effects on inflammation and survival. C-Myc over-expression was significantly associated with high sVEGF and normal sFlt-1 level in DLBCL patients, suggesting a complex interrelationship between c-Myc oncogene expression and angiogenic regulators. CLL B cells consistently express VEGFR1 mRNA; co-expression of angiogenic molecules and receptors suggest autocrine pathways of stimulation. Data suggest that vascular endothelial growth factor (VEGF) receptor flt-1 is expressed by eosinophils whose activation with VEGF stimulates directed migration and release of eosinophil cationic protein. During tumour progression there is a change in the relative amounts of sFIt-1 and vascular endothelial growth factor in the circulation. Effect of placenta growth factor-1 on proliferation and release of nitric oxide, cyclic AMP and cyclic GMP in human epithelial cells expressing the FLT-1 receptor. Expression of vascular endothelial growth factor and its receptor (Flt-1) in breast carcinoma. Granulocyte-Macrophage Colony-Stimulating Factor and monocytes play a vital role in angiogenesis through the regulation of VEGF and sVEGFR-1. In human umbilical vein endothelial cells, the Flt-1 receptor appears to act as a decoy receptor, tempering the response to lower concentrations of VEGF. In this study we give evidence of Flt-1 and KDR receptors in platelets. In vitro stimulation of blood samples with bacteria-derived antigens resulted in a significant increase in soluble VEGF (p < 0.0001) and a less pronounced but still significant increase in soluble VEGFR1. Increased expression of FLT1 is associated with an aggressive angiogenic phenotype in melanoma. Increased sFlt-1 secretion in first versus second pregnancies may account in part for the increased risk of preeclampsia among nulliparous women. Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. Oncogene FLT belongs to the src gene family and is related to oncogene ROS (MIM 165020). Like other members of this family, it shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation. The sequence structure of the FLT gene resembles that of the FMS gene (MIM 164770); hence, Yoshida et al. (1987) proposed the name FLT as an acronym for FMS-like tyrosine kinase.[supplied by OMIM]. Placental growth factor promotes recruitment of VEGFR1(+) hematopoietic stem cells from a quiescent to a proliferative bone marrow microenvironment, favoring differentiation, mobilization and reconstitution of hematopoiesis. Postmortem brain tissue analysis demonstrates VEGFR1 localized as paracellular deposits in Durck's granulomas of patients with cerebral malaria. Preeclamptic placental villous explants showed a four-fold increase in sVEGFR-1 over normal pregnancies. Elevated levels of sVEGFR-1 in preeclampsia are responsible for inhibiting angiogenesis. Relative to human VEGF165, the binding affinity of Pm venom VEGF to the human VEGFR-1 was 1.7-fold higher while affinity to the VEGFR-2 was 17-fold lower. But it did not bind the VEGFR-3 or neuropilin-1. Specific VEGFR1 expression, examined in 27 B-CLL samples, was positive in all of them. The VEGF transduction pathway may be very active in CLL cells. Both its paracrine & autocrine pathways may contribute to their enhanced survival. Staining for the receptors VEGFR-1 and VEGFR-2 was positive in large lymphoid cells in stage IV non-Hodgkin lymphoma. Subjects with acute mountain sickness have lower levels of soluble VEGF receptor (Flt-1) at both low and high altitude compared with well subjects. The expression of vascular endothelial growth factor and its receptors KDR and Flt-1 by gastric carcinoma tissues and cell lines was detected to elucidate the molecular mechanism of this growth factor in promoting tumor growth. There was a significant positive correlation between the level of expression of VEGF and VEGF-R1 (P = 0.04) in both control groups and lung bearing tumorlets. These data support the involvement in melanoma growth and survival of a VEGF-dependent internal autocrine loop mechanism, at least in vitro. These findings are consistent with the idea that the chemotactic effect of VEGF-A on mesenchymal progenitor cells (MPC) is mediated via VEGFR-1, and that VEGF-A and PlGF-1, have a functional role for recruitment of osteoprogenitor cells. This protein is a novel therapeutic target for angiogenic disorders (REVIEW). Up-regulation of VEGF-A receptor VEGFR-1 in capillaries in menorrhagia could be involved in abnormal endometrial vascular structure and permeability. VEGF and flt-1 are upregulated in blood vessels in many organs of acute Kawasaki Disease. VEGF and sFLT-1 can actively take part in the pathogenesis of diabetic nephropathy. VEGF receotor signaling regulates survival signals in CLL cells and that interruption of this autocrine pathway results in caspase activation and subsequent leukemic cell death. VEGF secreted by retinal pigment epithelial cells upregulates pigment epithelium-derived factor expression via VEGFR-1 in an autocrine manner. VEGF, VEGFR-1 and VEGFR-2 are concomitantly expressed in pre-B ALL cells. Expression of the receptors is limited to the intra-cytoplasmic compartment and may suggest either internalization or a block in trafficking of the receptor to the surface. VEGFR-1 secreted by endothelial cells becomes a matrix-associated protein that is able to interact with the alpha 5 beta 1 integrin; a new role of VEGFR-1 in angiogenesis. VEGFR1 initiates a clonogenic response in myeloid leukemia cells that is PI3-kinase dependent. When used individually, FGFR1 partially prevented goiter and sVEGFR1 partially reduced vascular volume. A basis for understanding molecular recognition between PlGF-1 and VEGFR1. Changing of transcriptional activity of VEGF gene and its receptor FLT-1 indicates an autocrine mechanism of regulation of angiogenic gene activity in the first step of carcinogenesis--low-grade intraepithelial lesions of the uterine cervix. Crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. Cytotrophobasts possess a unique property to enhance sFlt-1 production under reduced oxygen. Expression of VEGF receptor-1 in normal human epidermal keratinocytes; a role for VEGFR-1 in the proliferation of keratinocytes was found. Expression system is involved in angiogenesis in inflamed synovial tissue in the temporomandibular joint. Expression, purification and detection of biological activity. Findings demonstrate a requirement for VEGFR1+ haematopoietic progenitors in the regulation of metastasis, and suggest that expression patterns of fibronectin and VEGFR1+VLA-4+ clusters dictate organ-specific tumour spread. Findings may point to an involvement of soluble vascular endothelial growth factor receptor-1 in the pathophysiology of preeclampsia possibly by antagonizing vascular endothelial growth factor effects. Flt-1 appears to be important in the temporal regulation of oviductal secretion. Fms-like tyrosine kinase 1, a circulating antiangiogenic protein, may play an important role in the pathogenesis of preeclampsia [review]. Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor). In humans: 1) VEGF, KDR, and Flt-1 mRNA are increased by acute systemic exercise; 2) the time course of the VEGF, KDR, and Flt-1 mRNA responses are different from those previously reported in rats. In systemic lupus erythematosus patients the levels of VEGF and sVEGFR-1 are higher in patients with active SLE than in inactive disease or healthy persons. In vivo EPO does not affect the functionality and/or production of components of the VEGF/Flt-1 system in diabetics with normal or reduced renal function. MRNA expression of VEGF and its receptor flt-1 in the hydrosalpinx was significantly higher than that in the healthy oviduct. Overproduction of soluble VEGFR-1 may lead to suppression of VEGF-A and PlGF and the down-regulation of its membrane bound form (VEGFR-1) in the placental bed, may result in the defective uteroplacental development. Presence of an sVEGFR-1 in human serum and plasma of normal male and female donors strongly suggests that it plays an important role as a naturally occurring VEGF antagonist in the regulation and availability of VEGF-mediated biological activities in vivo. Results suggest that in the hematopoietic microenvironment an autocrine vascular endothelial growth factor loop contributes to optimal megakaryocytic maturation through Flt1. Role for sFlt-1 in the maternal manifestations of preeclampsia. Vitronectin increased the presence of all four growth factor receptors and most notably, VEGFR-1; in contrast, fibrin decreased all four receptors, especially FGFR-1 and FGFR-2.
|